<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Download Champions' AACR 2023 Poster

Pharmaco-Pheno-Multiomic Integration Builds a Biomarker Network of Olaparib Resistance in Ovarian Cancer 

 

Poster3236_AACR_ChampionsOncology_FINAL-1.pdf

 

 

Despite advances in ovarian cancer treatment, including PARP inhibitors for BRCA-mutated tumors, acquired resistance to therapy remains a challenge. This study identifies biomarkers linked to resistance to the PARP inhibitor Olaparib in platinum-pretreated ovarian cancer tumors, with Cyclin H and CDK7 expression emerging as key markers. Further analysis confirms CDK7 as a resistance biomarker in non-small cell lung cancer (NSCLC).

  • Ovarian cancer patients often experience recurrence after initial treatment, with PARP inhibitors offering some remission in BRCA-mutated cases.

  • The study identifies Cyclin H and CDK7 as biomarkers associated with resistance to Olaparib in ovarian cancer.

  • CDK7 expression is confirmed as a resistance biomarker for Olaparib, extending findings to NSCLC.

Download the Poster